Clinical trial
Efficacy, Safety and Cost-effectiveness of B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis: a Randomized Controlled Trial
NCT05296161 is registered in ClinicalTrials.gov with Amsterdam UMC, location VUmc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy, Safety and Cost-effectiveness of B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis: a Randomized Controlled Trial
- Lead sponsor
- Amsterdam UMC, location VUmc
- Phase
- Phase 4
- Overall status
- Active, not recruiting
- Start date
- April 20, 2022
- Completion date
- March 31, 2027
- Enrollment
- 296 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.